Genetic and Metabolic Disease in Children
This is a prospective, non-randomized, non-blinded observational study. The overarching goal is to discover new disease-associated genes in children, while establishing a specific focus on disorders where molecular characterization is most likely to lead to novel therapies. This study will merge detailed phenotypic characterization of patients presenting to the Pediatric Genetics and Metabolism Division in the Department of Pediatrics/Children's Medical Center at Dallas and collaborating clinics with Next-Generation sequencing techniques to identify disease-producing mutations. The primary objective of the study is to identify novel pathogenic mutations in children with rare Mendelian disorders. A secondary objective of the study is to establish normative ranges of a large number of metabolites from healthy newborns and older children.
Conditions:
🦠 Genetic Diseases 🦠 Metabolic Diseases
🗓️ Study Start (Actual) June 2015
🗓️ Primary Completion (Estimated) May 2025
✅ Study Completion (Estimated) May 2025
👥 Enrollment (Estimated) 1550
🔬 Study Type OBSERVATIONAL
📊 Phase N/A
Locations:
📍 Dallas, Texas, United States

📋 Eligibility Criteria

Description

  • Inclusion criteria of Cohort 1- Newborn:
  • * Subjects aged 1-2 days
  • * Subjects with gestational age 37-42 weeks
  • * Subjects with stable clinical status (admitted to normal newborn nursery)
  • Inclusion criteria of Cohort 2 - Older children:
  • • Subjects aged 0-18 years
  • Inclusion criteria of Cohort 3 - Diseased children:
  • Subjects (no age limit) with ANY phenotype as below:
  • * Confirmed metabolic or genetic diseases
  • * Suspected metabolic or genetic diseases
  • * Episodic metabolic decompensation (e.g. hypoglycemia, hyperammonemia, metabolic acidosis)
  • * Developmental regression
  • * Major congenital malformation
  • * Other unexplained symptoms of potential genetic origin
  • Exclusion criteria of Cohort 1 - Newborn:
  • * Subjects with gestational age \<37 weeks or \>42 weeks
  • * Subjects with overt signs of metabolic dysfunction, distress or genetic diseases including hypoglycemia, hyperglycemia, sepsis/shock, hypoxemia, or major congenital malformation
  • * Subjects with mothers whose pregnancies were complicated by gestational diabetes, gestational hyperglycemia, gestational hypertension, preeclampsia, or any other major disorders.
  • Exclusion criteria of Cohort 2 - Older children:
  • * Subjects with confirmed metabolic or genetic diseases
  • * Subjects with suspected metabolic or genetic diseases
  • * Subjects with episodic metabolic decompensation (e.g. hypoglycemia, hyperammonemia, metabolic acidosis)
  • * Subjects with developmental regression
  • * Subjects with major congenital malformation
  • Exclusion criteria of Cohort 3 - Diseased children No.
Ages Eligible for Study: 1 Day to N/A (CHILD, ADULT, OLDER_ADULT)
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No

🗓️ Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

  • First Submitted 6 January 2016
  • First Submitted that Met QC Criteria 7 January 2016
  • First Posted 8 January 2016

Study Record Updates

  • Last Update Submitted that Met QC Criteria 12 June 2024
  • Last Update Posted 13 June 2024
  • Last Verified June 2024